Abstract: There is provided an ophthalmic preparation comprising a fat emulsion containing flurbiprofen or its derivative such as ester as an active ingredient.

Abstract: A method of producing immunoglobulin preparations for intravenous injection which starts with an immunoblobulin-containing fraction and comprises the treatment steps of:(a) treating said fraction with 4-10 weight/volume percent of polyethylene glycol having a molecular weight of 1,000-10,000 under conditions of pH 4-6, ion strength 0.0001-0.1M and temperature 0.degree.-4.degree. C. and recovering the supernatant,(b) treating the supernatant obtained in step (a) with 10-15 weight/volume percent of polyethylene glycol having a molecular weight of 1,000-10,000 under conditions of pH 6-9, ion strength 0.0001-0.1M and temperature 0.degree.-4.degree. C. and recovering the resulting precipitate, and(c) heat-treating, in any desired step, said immunoglobulin in the presence of a stabilizer under conditions sufficient to inactivate contaminant viruses.

Abstract: A therapeutic and prophylactic agent for peptic ulcers which contains as an active ingredient a compound of the general formula (I): ##STR1## wherein R.sub.1 represents hydrogen or .dbd.O; R.sub.2 represents hydrogen or --OR.sub.5 ; R.sub.3 represents hydrogen or --OR.sub.5 ; R.sub.4 represents --OR.sub.7 in the case of the absence of double bond; R.sub.5, R.sub.6 and R.sub.7 each represents hydrogen or an organic residue;X represents group (A);.dbd.C.dbd.CH--COR.sub.8 (A)or group (B): ##STR2## wherein R.sub.8 represents alkyl, and R.sub.9 and R.sub.10 each represents hydrogen or an organic residue; with the proviso that when X represents group (A), then R.sub.1 and R.sub.3 both represent hydrogen, R.sub.2 represents --OR.sub.5, R.sub.4 represents OR.sub.7 and the bond between the carbon atom to which X is attached and the carbon atom to which R.sub.4 is attached is a single bond, and when X represents group (B), then R.sub.1 represents .dbd.O, R.sub.2 represents hydrogen, R.sub.3 represents --OR.sub.

Abstract: A DNA sequence of the yeast glyceraldehyde-3-phosphate dehydrogenase (GAP-DH) promoter and a process for preparing a heterologous protein utilizing said DNA sequence as a promoter are disclosed, said GAP-DH promoter comprising a region upstream of an initiator codon of the GAP-DH protein up to -164 bp as a minimum unit. Since the GAP-DH promoter is small in size, a physiologically active substance can be expressed in yeasts effectively and recombination of DNA can be simplified.

Abstract: A monoclonal antibody is described, having a specific reactivity with a cancer-associated antigen selected from pancreas cancer-associated antigen, intestinum crassum cancer-associated antigen and hepatoma-associated antigen and has the following characteristics:(1) it exists in a blood serum of pancreas cancer, intestinum crassum cancer and hepatoma patients;(2) it comprises glycoproteins;(3) it has a molecular weight of about 700,000 to 1,500,000, as measured by gel-filtration and determined by comparison with that of a known protein;(4) it has a maximum absorption of 2800 nm when dissolved in 0.1 M acetic acid buffer solution (pH 4.5); and(5) it is released at least in a cultured supernatant medium of establihed cell line of COLO-201, TE-1, TE-2, TE-3, NRC-12, MKN-45 and KATO III. The monoclonal antibody is utilized as a reagent for detecting pancreas cancer, intestinum crassum cancer and hepatoma. A process for preparing the monoclonal antibody and a process for preparing the reagent are also disclosed.

Abstract: A method of producing a heterologous protein in yeast is disclosed, which comprises transforming a yeast Saccharomyces cerevisiae with recombinant DNA comprising a promoter selected from the group consisting of a yeast promoter or a hybrid promoter derived from a yeast promoter, particularly a hybrid promoter containing the enhancer region of SV40 virus, and a gene coding for a heterologous protein such as HBsAg and Pre S-HBsAg, particularly full length Pre S-HBsAg culturing, the resulting transformed cells to express the gene coding the heterologous protein, and isolating the heterologous protein from the cultured medium. GAP-DH and PH05 promoters and miniaturized ones can be used as the yeast promoter. The expression of the full length Pre S-HBsAg is carried out in the same expression system as that for 2nd or 3rd Pre S-ABsAg.

Abstract: A therapeutic and prophylactic agent for peptic ulcers which contains as an active ingredient a compound of the general formula (I): ##STR1## wherein R.sub.1 represents hydrogen or =O; R.sub.2 represents hydrogen or --OR.sub.5 ; R.sub.3 represents hydrogen or --OR.sub.6 ; R.sub.4 represents --OR.sub.7 in the case of the absence of double bond; R.sub.5, R.sub.6 and R.sub.7 each represents hydrogen or an organic residue;X represents group (A):.dbd.C.dbd.CH--COR.sub.8 (A)or group (B): ##STR2## wherein R.sub.8 represents alkyl, and R.sub.9 and R.sub.10 each represents hydrogen or an organic residue; with the proviso that when X represents group (A), then R.sub.1 and R.sub.3 both represent hydrogen, R.sub.2 represents --OR.sub.5 ; R.sub.4 represents OR.sub.7 and the bond between the carbon atoms to which X is attached and the carbon atom to which R.sub.4 is attached is a single bond, and when X represents group (B), then R.sub.1 represents .dbd.O, R.sub.2 represents hydrogen, R.sub.3 represents --OR.sub.

Abstract: A pharmaceutical composition comprises a benzoyl urea compound having the formula: ##STR1## wherein X is a nitro group, Y is a chlorine atom, Z.sub.2 is a hydrogen atom, Z.sub.1 is a halogen atom, and A is a nitrogen atom, and at least one member selected from the group consisting of a cyclodextrin, a polyethylene glycol and a refined oil.

Abstract: A fat emulsion containing a prostaglandin E.sub.1 alkyl ester represented by the general formula ##STR1## wherein R denotes an alkyl group having 1 to 30 carbon atoms. The fat emulsion can be administered intravenously, has a long half-life of its effective ingredient, prostaglandin E.sub.1 alkyl ester, in the living body as well as a focus selectivity.

Abstract: A method for purifying factor VIII complex comprising: (A) absorbing an impure extract containing factor VIII complex on a water-insoluble carrier, and (B) recovering factor VIII complex in the unadsorbed fractions, wherein said water-insoluble carrier contains as a ligand a group represented by the formula (I) or (II):--(CH.sub.2).sub.n --NH.sub.2 (I) or--(CH.sub.2).sub.n --CHO (II)wherein n is an integer of from 3 to 10.

Abstract: A recombinant plasmid wherein at least two DNA fragments containing a Baker gene and a Charlie gene of the yeast 2 .mu.m circular plasmid are incorporated into a plasmid containing genes encoding a physiologically active substance is disclosed. Also, a strain transformed by the recombinant plasmid is disclosed.

Abstract: A lipoxygenase inhibitor comprising as active ingredient a substituted styrene derivative having a radical of the general formula ##STR1## wherein X denotes a hydroxyl group or a lower alkoxy group and q is an integer of 2 or 3, and containing carbon atoms in total of at least 8.

Abstract: Virus-contaminated immunoglobulin can be virus-inactivated by heating it in a substantially dry state at a temperature of 30.degree. to 100.degree. C. for a period of time sufficient for inactivating virus with maintaining original activity of the immunoglobulin. The addition of glycine, sodium chloride, sodium acetate, polyethylene glycol, albumin or mannitol enhances the effect and gives good solubility and good state to the solution of the virus-inactivated immunoglobulin.

Abstract: A novel compound of the formula, ##STR1## wherein R denotes a lower perfluoroalkyl group, l is an integer of 3 or 4, n+m is an integer of 2 or 3, provided that n may be zero, and at least one of ring A and ring B may be substituted by a lower perfluoroalkyl group, prepared by reacting the corresponding perhydro compound with fluorine is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation.

Abstract: A process for the purification of HBsAg is disclosed, which comprises adsorbing specifically on a carrier, in the presence of an inorganic salt in an amount of 5 to 25 W/V %, an HBsAg obtained by gene engineering.

Abstract: The invention provides a method of producing a water-soluble complex comprising a water-insoluble drug and a phospholipid, comprising the steps of (1) dissolving a water-insoluble drug and a phospholipid in an organic solvent, (2) removing the solvent to leave behind a drug-containing phospholipid film, (3) suspending the resulting film in an aqueous solution, (4) ultrasonicating the film, (5) centrifuging the resulting suspension, and (6) recovering the lowermost layer of the resulting sediment to yield the water-soluble complex. The above complex can be administered parenterally as well as by the oral and other routes, and is so rich in the drug component that a remarkably increased drug activity can be realized.

Abstract: A novel compound of the formula, ##STR1## wherein k is zero or an integer of 1 to 2, j is an integer of from 1 or 3, l and m are each zero or an integer of from 1 to 3, and n is an integer of from 1 to 4, the rings A, B and C being optionally substituted with at least one trifluoromethyl group or tetrafluoroethyl group is prepared by reacting the perhydro compound corresponding thereto with fluorine. The compound is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation.

Abstract: A reagent for determination of human blood coagulation factor XIII for reversed passive hemagglutination reaction which comprises sensitized erythrocytes prepared by sensitizing animal erythrocytes with specific anti-human factor XIII antibody, and a kit using the reagent are disclosed.

Abstract: A novel compound of the formula, ##STR1## wherein k is zero or an integer of 1 to 2, j is an integer of from 1 or 3, l and m are each zero or an integer of from 1 to 3, and n is an integer of from 1 to 4, the rings A, B and C being optionally substituted with at least one trifluoromethyl group or tetrafluoroethyl group is prepared by reacting the perhydro compound corresponding thereto with fluorine. The compound is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation.

Abstract: There is provided a fat emulsion of an ester of flurbiprofen having the formula ##STR1## wherein R is a group of the formula ##STR2## wherein R.sub.1 is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group, R.sub.2 is a C.sub.1 -C.sub.15 alkyl group or a C.sub.2 -C.sub.8 alkenyl group, and m is zero or an integer of 1; or a lactone group of the formula ##STR3## wherein R.sub.3 and R.sub.4 are same as or different from each other and are a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group, and n is an integer of 1 or 2.The emulsion containing particles of a vegetable oil dissolving the ester can be orally or parenterally administered to human or animal for analgesia, antiphlogosis and antipyresis in various diseases and exhibits a high activity with small amounts in terms of flurbiprofen as compared with flurbiprofen itself.